- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Tubular proteinuria.
Displaying page 1 of 1.
| EudraCT Number: 2016-005081-60 | Sponsor Protocol Number: RENAL-AAD | Start Date*: 2017-04-21 |
| Sponsor Name:Jose Luis Calleja Panero | ||
| Full Title: MULTICENTER CLINICAL TRIAL TO DETERMINE THE INFLUENCE OF TREATMENT WITH DIRECT ANTIVIRAL AGENTS IN THE GLOMERULAR AND TUBULAR FUNCTION OF PATIENTS WITH CHRONIC HCV HEPATITIS | ||
| Medical condition: Hepatitis C | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-000553-23 | Sponsor Protocol Number: GBG66 | Start Date*: 2011-09-29 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:German Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: patients with triple-negative breast cancer, patients with HER2-positive early breast cancer | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-000331-16 | Sponsor Protocol Number: C-935788-050 | Start Date*: 2014-07-28 |
| Sponsor Name:Rigel Pharmaceuticals Inc | ||
| Full Title: A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy | ||
| Medical condition: IgA nephropathy (IgAN) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) AT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-004692-22 | Sponsor Protocol Number: NA | Start Date*: 2015-11-19 |
| Sponsor Name:University of Torino | ||
| Full Title: MARAT Study “Pharmacokinetics of MARaviroc and boosted ATazanavir dual regimen in stable HIV-infected patients” | ||
| Medical condition: HIV infection | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-005855-19 | Sponsor Protocol Number: BCX9930-211 | Start Date*: 2021-10-11 | |||||||||||||||||||||
| Sponsor Name:BioCryst Pharmaceuticals Inc | |||||||||||||||||||||||
| Full Title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy | |||||||||||||||||||||||
| Medical condition: complement 3 glomerulopathy immunoglobulin A nephropathy primary membranous nephropathy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2010-024381-21 | Sponsor Protocol Number: CRAD001A2314 | Start Date*: 2011-07-29 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination c... | |||||||||||||
| Medical condition: Prevention of acute rejection in paediatric recipients of a renal transplant | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) BE (Completed) FR (Completed) DE (Completed) NO (Completed) IT (Completed) Outside EU/EEA SE (Completed) GB (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002518-35 | Sponsor Protocol Number: 2011-402 | Start Date*: 2012-02-22 | |||||||||||
| Sponsor Name:Karl Emil Kristensen | |||||||||||||
| Full Title: The effect of aldosterone on the development of chronic allograft nephropathy after kidney transplantation | |||||||||||||
| Medical condition: Chronic allograft nephropathy in kidney transplants, defined as tubular atrophy and interstitial fibrosis in graft biopsy (Banff criteria) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002985-15 | Sponsor Protocol Number: MOR202C205 | Start Date*: 2020-10-12 | |||||||||||
| Sponsor Name:MorphoSys AG | |||||||||||||
| Full Title: A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (N... | |||||||||||||
| Medical condition: Anti-PLA2R antibody positive membranous nephropathy (aMN) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000550-60 | Sponsor Protocol Number: V7/22032018 | Start Date*: 2014-01-17 | |||||||||||
| Sponsor Name:Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 3 | |||||||||||||
| Full Title: Pulsed oral sirolimus in autosomal dominant polycystic kidney disease | |||||||||||||
| Medical condition: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and uncontrolled proliferation of innumerable epithelial-lined cysts that stem from renal... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-022120-72 | Sponsor Protocol Number: JF-001 | Start Date*: 2010-12-17 | ||||||||||||||||||||||||||
| Sponsor Name:Guy's & St. Thomas' NHS Foundation Trust | ||||||||||||||||||||||||||||
| Full Title: The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1-infected patients (MIDAs). | ||||||||||||||||||||||||||||
| Medical condition: HIV | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2006-003502-26 | Sponsor Protocol Number: ESA-1 | Start Date*: 2006-12-14 | |||||||||||
| Sponsor Name:Barts and the London NHS Trust | |||||||||||||
| Full Title: A randomised control trial of the use of Epoetin Beta in the treatment of Post Transplant Anaemia | |||||||||||||
| Medical condition: Post Transplant Anaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003298-24 | Sponsor Protocol Number: EVITAESTEROIDE-12 | Start Date*: 2014-06-26 | |||||||||||
| Sponsor Name:Sociedad Andaluza de Trasplante de Órganos y Tejidos (SATOT) | |||||||||||||
| Full Title: Steroid withdrawal and novo donor-specific anti-HLA antibodies in renal transplant patients: a prospective, randomized and controlled study in parallel groups. | |||||||||||||
| Medical condition: Kidney transplantaion | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000726-10 | Sponsor Protocol Number: ADAPT | Start Date*: 2021-06-23 | |||||||||||
| Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||
| Full Title: Evaluating the short-term renal and systemic effects of Dapagliflozin in non-diabetic patients with stage IV CKD at risk of ESKD because of severe renal insufficiency and persistent proteinuria: A ... | |||||||||||||
| Medical condition: Non-diabetic stage IV Chronic Kidney Disease (CKD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-003345-29 | Sponsor Protocol Number: 3568 | Start Date*: 2016-11-16 | |||||||||||
| Sponsor Name:Kings College Hospital NHS Foundation Trust | |||||||||||||
| Full Title: Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF) | |||||||||||||
| Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-003195-12 | Sponsor Protocol Number: CHUBX2012/29 | Start Date*: 2013-10-01 |
| Sponsor Name:CHU de Bordeaux | ||
| Full Title: A multicenter, two arms, randomized, open label clinical Phase IV study investigating the proportion of CMV seropositive kidney transplant recipients who will develop a CMV infection within the fir... | ||
| Medical condition: CMV infection in CMV-seropositive de novo kidney transplant recipients receiving an immunosuppressive regimen. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003089-11 | Sponsor Protocol Number: ICI21/00042 | Start Date*: 2022-03-08 | ||||||||||||||||
| Sponsor Name:Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC) | ||||||||||||||||||
| Full Title: Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients: a Spanish Multicenter, Randomized, Controlled Parallel-group Trial: The TRAINING Study | ||||||||||||||||||
| Medical condition: Subclinical inflammation, including borderline lesions (BL), is very common after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-000780-24 | Sponsor Protocol Number: MOR202C103 | Start Date*: 2019-09-24 | |||||||||||
| Sponsor Name:MorphoSys AG | |||||||||||||
| Full Title: A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE | |||||||||||||
| Medical condition: Primary (anti-PLA2R antibody positive) Membranous Nephropathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-003200-39 | Sponsor Protocol Number: 13/0077 | Start Date*: 2014-04-01 | ||||||||||||||||||||||||||
| Sponsor Name:University College London | ||||||||||||||||||||||||||||
| Full Title: A phase II, single centre, randomised, placebo-controlled, 3-part trial to assess the safety, tolerability and efficacy of Zibotentan in patients with renal disease secondary to scleroderma | ||||||||||||||||||||||||||||
| Medical condition: Renal complications of systemic sclerosis (scleroderma renal crisis and chronic kidney disease). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.